Merus N. V. 股票在对头部和颈部癌治疗进行有希望的第二阶段试验结果后猛涨35%。 Merus N.V. stock soars 35% after promising phase 2 trial results for head and neck cancer treatment.

Merus NV 的股价上涨了 35% 以上，此前该公司报告了 petrosemtamab 和 pembrolizumab 联合治疗头颈癌的 2 期试验的积极中期结果。 Merus N.V.'s stock jumped over 35% after reporting positive interim results from a phase 2 trial for a treatment combining petrosemtamab and pembrolizumab for head and neck cancer. 试验显示,43名病人在12个月后,有63%的回复率和79%的存活率,没有重大毒性。 The trial showed a 63% response rate and 79% survival rate at 12 months among 43 patients, with no significant toxicities. 分析师提高了价格目标,该公司预计2026年将获得第3阶段的数据。 Analysts raised price targets, and the company is expecting phase 3 data in 2026.